ArticleJournal of inflammation research2026
Downregulation of UNC5B-AS1 in Preterm Infants with Bronchopulmonary Dysplasia and Its Protective Mechanism via the miR-134-5p/IGF1 Axis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Bronchopulmonary dysplasia (BPD) is a major chronic lung disease in preterm infants. This study was designed to elucidate the functional significance and molecular mechanism of the long non-coding RNA UNC5B-AS1 in BPD pathogenesis. Clinical Samples and Cell Assays: This study included 50 preterm infants with BPD and 42 healthy newborns. The levels of UNC5B-AS1, miR-134-5p, IGF1, Bax, and Bcl-2 were detected by RT-qPCR. In in vitro experiments, A549 and MLE-12 cells were used to establish a hyperoxia-induced BPD model. A series of assays was performed to evaluate the cellular phenotypes, including CCK-8 for viability, flow cytometry for apoptosis, ELISA for inflammatory factors (TNF-α, IL-1β, IL-6), and SOD activity, and DCFH-DA probing for ROS levels. IGF1 protein expression was examined by Western blot. Dual-luciferase reporter assay and RIP experiments were performed to validate the targeting relationships between UNC5B-AS1 and miR-134-5p, and between miR-134-5p and IGF1. Results: Serum levels of UNC5B-AS1 were significantly downregulated, while miR-134-5p expression was significantly upregulated in BPD infants, both showing good diagnostic value. UNC5B-AS1 directly binds to miR-134-5p. In the cellular model, the protective effect of UNC5B-AS1 overexpression against hyperoxia-induced injury was reversed by miR-134-5p overexpression. Furthermore, IGF1 was confirmed as a direct target of miR‑134‑5p, and knockdown of IGF1 abolished the protective effects achieved by miR‑134‑5p inhibition. Conclusion: Serum UNC5B‑AS1 is downregulated and miR‑134‑5p is upregulated in preterm BPD infants. Mechanistically, UNC5B‑AS1 may sponges miR‑134‑5p to upregulate IGF1, protecting against hyperoxia‑induced alveolar injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.